Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
16
pubmed:dateCreated
1999-9-2
pubmed:abstractText
CP-060 (1), 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-[3-[N-methyl-N-[2-[3, 4-(methylenedioxy)phenoxy]ethyl]amino]propyl]-1,3-thiazolidin-4-on e, is a novel type of Ca(2+) antagonist possessing both Ca(2+) overload inhibition and antioxidant activity. The structure-activity relationships for this series of compounds were studied by synthesizing the analogues and evaluating these three kinds of activity. Ca(2+) antagonistic activity was largely determined by the lipophilicity of the phenyl group at the 2-position and the length of the alkyl chains. As for the antioxidant activity, it was demonstrated that the phenolic hydroxyl group is an essential structural element. Compounds with potent activity were evaluated for their effect on the coronary blood flow in vivo. Among these compounds, compound 1 was shown to be the most potent. Furthermore, the enantiomers of 1 were resolved by high-performance liquid chromatography with a chiral column. Compound (-)-1 showed about 10 times higher Ca(2+) antagonistic activity than (+)-1, though both enantiomers had similar potency in Ca(2+) overload inhibition and antioxidant activity. An X-ray crystal structure determination of (-)-1 hydrogen fumarate identified (-)-1 as having S configuration at the 2-position.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3134-46
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10447958-Animals, pubmed-meshheading:10447958-Antioxidants, pubmed-meshheading:10447958-Aorta, pubmed-meshheading:10447958-Calcium, pubmed-meshheading:10447958-Calcium Channels, pubmed-meshheading:10447958-Calcium Channels, L-Type, pubmed-meshheading:10447958-Chromatography, High Pressure Liquid, pubmed-meshheading:10447958-Coronary Circulation, pubmed-meshheading:10447958-Crystallography, X-Ray, pubmed-meshheading:10447958-Dogs, pubmed-meshheading:10447958-Lipid Peroxidation, pubmed-meshheading:10447958-Lipoproteins, LDL, pubmed-meshheading:10447958-Lipoxygenase, pubmed-meshheading:10447958-Male, pubmed-meshheading:10447958-Models, Molecular, pubmed-meshheading:10447958-Muscle, Smooth, Vascular, pubmed-meshheading:10447958-Myocardium, pubmed-meshheading:10447958-Phenols, pubmed-meshheading:10447958-Rabbits, pubmed-meshheading:10447958-Rats, pubmed-meshheading:10447958-Rats, Sprague-Dawley, pubmed-meshheading:10447958-Soybeans, pubmed-meshheading:10447958-Stereoisomerism, pubmed-meshheading:10447958-Structure-Activity Relationship, pubmed-meshheading:10447958-Thiazoles, pubmed-meshheading:10447958-Thiazolidines
pubmed:year
1999
pubmed:articleTitle
Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 2. Structure-activity relationships of thiazolidinone derivatives.
pubmed:affiliation
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan.
pubmed:publicationType
Journal Article, In Vitro